Dataset: Expression data from Bone-Marrow Mesenchymal Stromal Cells (BM-MSC) from Follicular Lymphoma patient (FL) or Healthy Donor (HD).

Human bone marrow mesenchymal stromal cells (BM-MSC) could be committed toward a functional lymphoid-like stroma by a combination of...

Registered by ArrayExpress Uploader

View Dataset

Human bone marrow mesenchymal stromal cells (BM-MSC) could be committed toward a functional lymphoid-like stroma by a combination of TNFalpha (TNF) and Lymphotoxin alpha1/beta2 (LT) (Amé-Thomas et al Blood 2007). Bone marrow and lymph node stromal cells support FL malignant cell recruitment and growth in particular after comittment to a lymphoid-like differentiation in vitro. In addition, more than 70% of FL patients exhibit a bone marrow involvment at diagnosis. We delineate using Affymetrix U133+2.0 microarrays the gene expression profile of BM-MSC obtained from FL patients (FL-MSC) and age-matched healthy donors (HD-MSC) in order to identify a specific FL-MSC signature. In addition, we used Affymetrix microarrays to define the gene expression signature of lymphoid-like stromal cells obtained from HD-MSC by treatment with TNF/LT in vitro. This TNF/LT signature was then used to interpret the gene expression profile of FL-MSC. GEP was performed on 10 BM-MSC from FL patients and 6 from healthy donors, treated or not with TNF(10 ng/mL)/LT(100ng/mL)

Species:: human
Samples:: 28
Source:: E-GEOD-35331
Updated:: Dec.12, 2014
Registered:: Sep.19, 2014

Factors: (via ArrayExpress)

Sample	GROWTH PROTOCOL	GENDER	PATHOLOGY	AGE (Y)	TREATMENT
GSM866168	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Healthy donor	55	Untreated
GSM866169	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Healthy donor	53	Untreated
GSM866170	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Healthy donor	30	Untreated
GSM86617	alphaMEM+10%FBS+FGF2(1ng/mL)	female	Healthy donor	68	Untreated
GSM866169	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Healthy donor	53	Untreated
GSM866173	alphaMEM+10%FBS+FGF2(1ng/mL)	female	Healthy donor	78	Untreated
GSM866174	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Follicular Lymphoma patient	68	Untreated
GSM866175	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Follicular Lymphoma patient	55	Untreated
GSM866176	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Follicular Lymphoma patient	76	Untreated
GSM866177	alphaMEM+10%FBS+FGF2(1ng/mL)	female	Follicular Lymphoma patient	53	Untreated
GSM866178	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Follicular Lymphoma patient	73	Untreated
GSM866179	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Follicular Lymphoma patient	61	Untreated
GSM866180	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Follicular Lymphoma patient	47	Untreated
GSM86618	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Follicular Lymphoma patient	56	Untreated
GSM866182	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Follicular Lymphoma patient	42	Untreated
GSM866183	alphaMEM+10%FBS+FGF2(1ng/mL)	female	Follicular Lymphoma patient	66	Untreated
GSM866168	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Healthy donor	55	Untreated
GSM866169	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Healthy donor	53	Untreated
GSM866170	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Healthy donor	30	Untreated
GSM86617	alphaMEM+10%FBS+FGF2(1ng/mL)	female	Healthy donor	68	Untreated
GSM866169	alphaMEM+10%FBS+FGF2(1ng/mL)	male	Healthy donor	53	Untreated
GSM866173	alphaMEM+10%FBS+FGF2(1ng/mL)	female	Healthy donor	78	Untreated
GSM866190	RPMI1640+10%FBS	male	Healthy donor	55	Stimulated by TNF+LT for 3 days
GSM86619	RPMI1640+10%FBS	male	Healthy donor	53	Stimulated by TNF+LT for 3 days
GSM866192	RPMI1640+10%FBS	male	Healthy donor	30	Stimulated by TNF+LT for 3 days
GSM866193	RPMI1640+10%FBS	female	Healthy donor	68	Stimulated by TNF+LT for 3 days
GSM86619	RPMI1640+10%FBS	male	Healthy donor	53	Stimulated by TNF+LT for 3 days
GSM866195	RPMI1640+10%FBS	female	Healthy donor	78	Stimulated by TNF+LT for 3 days